Incidence of Drug Interaction When Using Proton Pump Inhibitor and Warfarin According to Cytochrome P450 2C19 (CYP2C19) Genotype in Japanese

Abstract

Objectives The US Food and Drug Administration has suggested that proton pump inhibitors (PPIs) increase the international normalized ratio (INR) when used concomitantly with warfarin (WF) because of being metabolized by cytochrome P450 2C19 (CYP2C19). We assessed whether CYP2C19 genotypes and type of PPI accentuated the drug interaction.

Methods and Results The study group was 82 patients who needed WF after surgery and had their CYP2C19 genotypes analyzed in advance. We randomly divided them into two groups: group I (n = 41) included patients who had lansoprazole 15 mg/day and group II (n = 41) included patients who had rabeprazole 10 mg/day. The dose of WF was controlled by the doctor in charge as a target INR of 1.6 to 2.6 during the 2 months after surgery. The maximum INR was significantly higher in group I (3.36 ± 0.98) than in group II (2.29 ± 0.55, p < 0.0001). The incidence of over-INR (> 3.5) was significantly higher in group I (15 cases) than in group II (2 cases, p = 0.0001). Several bleeding events complicated 10 patients in group I, but none in group II (p = 0.015). Logistic regression analysis revealed that over-INR (odds ratio [OR] 3.58, 95% confidence interval [CI]: 3.48–368.25, p < 0.0001), and pair of lansoprazole and CYP2C19 intermediate metabolizer (OR 2.39, 95% CI: 1.108–29.491, p = 0.0009) were independent predictors of bleeding events.

Conclusion If a patient has had the intermediate metabolizer CYP2C19 genotype and concomitant use of WF and a PPI after open heart surgery, lansoprazole intensifies the effects of WF and is associated with bleeding events.

Keywords

open heart surgery - anticoagulant therapy - proton pump inhibitor

• References

• 1 Hata M, Shiono M, Sekino H , et al. Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circ J 2005; 69 (3) 331-334
• 2 Hata M, Shiono M, Sekino H , et al. Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery. Surg Today 2006; 36 (2) 131-134
• 3 Hata M, Hayasaka M, Sezai A , et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg 2008; 56 (5) 274-277
• 4 Available at: http://www.fda.gov/medwatch/SAFETY/2006/Apr_PIs/Naprapac_PI.pdf . See 15–16
• 5 de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269 (22) 15419-15422
• 6 McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther 2003; 10 (5) 330-340
• 7 Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40 (8) 587-603
• 8 Glance LG, Osler TM, Mukamel DB, Dick AW. Effect of complications on mortality after coronary artery bypass grafting surgery: evidence from New York State. J Thorac Cardiovasc Surg 2007; 134 (1) 53-58
• 9 Millican EA, Lenzini PA, Milligan PE , et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110 (5) 1511-1515
• 10 Schwarz UI, Ritchie MD, Bradford Y , et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358 (10) 999-1008
• 11 Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis 2009; 43 (1) 119-128
• 12 Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60 (6) 661-666
• 13 Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (3, Suppl): 287S-310S
• 14 Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65 (4) 365-375
• 15 Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 (Suppl. 01) S21-S25
• 16 Andersson T, Miners JO, Veronese ME , et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36 (6) 521-530
• 17 Yasuda S, Horai Y, Tomono Y , et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58 (2) 143-154
• 18 Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl. 03) 27-36
• 19 Anderson JL, Horne BD, Stevens SM , et al; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116 (22) 2563-2570